Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
Abstract: Methods of increasing skeletal muscle protein synthesis in a subject are provided. Methods of increasing or maintaining mammalian target of rapamycin (mTOR) activation are also provided. Such methods include a step of administering at least one serving per day of a composition including 20 to 2,000 mg of a green tea extract per serving to the subject.
Type:
Application
Filed:
December 8, 2014
Publication date:
December 15, 2016
Applicant:
ABBOTT LABORATORIES
Inventors:
BENJAMIN MEADOR, SUZETTE PEREIRA, NEILE EDENS, MICHAEL TISDALE
Abstract: Methods and compositions are provided for increasing or enhancing the efficacy of antibiotics, such as by increasing antimicrobial activity, against a variety of microbes by co-administration with synthetic amphiphiles, including lariat ethers and hydraphiles. Methods and compositions for overcoming antibiotic resistance are also provided.
Type:
Application
Filed:
June 17, 2016
Publication date:
December 15, 2016
Inventors:
George W. Gokel, Michael R. Gokel, Saeedeh Negin, Mohit B. Patel
Abstract: The invention relates to a nanostructured (nanoparticular) composition comprising Indomethacine, its pharmaceutically acceptable salts and co-crystals, processes for the preparation thereof, and compositions useful for pharmaceutical applications. The size of the nanoparticles according to the invention is smaller than 500 nm. Indomethacine (INN) or Indomethacine (USAN, previously BAN) is a non-steroidal anti-inflammatory drug (NSAID), which is used for the treatment of fever, inflammation, spasm, swells and inflammations. The machanism of action of Indomethacine is the inhibition of the synthesis of prostaglandin. It is marketed under the trade names of Indocin, Indocid, Indochron E-R, and Indocin-SR.
Type:
Application
Filed:
February 25, 2015
Publication date:
December 15, 2016
Applicant:
DARHOLDING KFT.
Inventors:
Genovéva FILIPCSEI, Zsolt ÖTVÖS, Gábor HELTOVICS, Ferenc DARVAS
Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Inventors:
Nadja GRUENING, Marc SCHILLER, Ashish HEMANI, Chris KIRBY, Ingo FRIEDRICH, John BOTHMER, Andreas SCHOLZ
Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, and C6-12-aralkyl; or R3 and R4 are each independently selected from C1-6-alkyl and halo; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Inventors:
Martin QUIBELL, John P. WATTS, Nicholas S. FLINN
Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment of REM sleep behavior disorder.
Type:
Application
Filed:
June 10, 2016
Publication date:
December 15, 2016
Inventors:
Lawrence Tim FRIEDHOFF, Shankar RAMASWAMY, Warren WEN
Abstract: The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of fipronil to its sulfone, and their uses in topical applications on animals and the environment. Useful formulations comprise from about 30% to about 55% (w/w) permethrin and about 2 to 15% (w/w) fipronil and a solvent system that comprises N-methyl pyrrolidone and a glycol, glycol ether, glycol ester, fatty acid ester or neutral oil, wherein the N-methyl pyrrolidone and glycol, glycol ether, glycol ester, fatty acid ester or neutral oil are present in a weight: weight ratio of from about 1:2.0 to about 1:3.5, glycol, glycol ether, glycol ester, fatty acid ester or neutral oil to n-methyl pyrrolidone. These two actives when combined in the described amounts have been found to have unexpected enhanced repellent activity against stable fly.
Type:
Application
Filed:
August 26, 2016
Publication date:
December 15, 2016
Applicant:
MERIAL, INC.
Inventors:
Mark David Soll, James Pate, Lisa A. Baker
Abstract: Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective amount of at least one inhibitor of tryptophan 2,3-dioxygenase (TDO) and/or indoleamine 2,3-dioxygenase (IDO), optionally combined with one or more additional anti-cancer agents.
Type:
Application
Filed:
June 10, 2016
Publication date:
December 15, 2016
Inventors:
Paul Novick, Jonathan Choy, Sumit Mahajan, Ritika Prasad, Shalabh Gupta
Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H.
Abstract: The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a Rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient. The therapeutic amount may be effective to attenuate graft-versus-host disease and to preserve the graft-versus-tumor effect of the transplant.
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
Type:
Application
Filed:
December 9, 2014
Publication date:
December 15, 2016
Inventors:
JOHN P. LEONARD, JEAN-FRANÇOIS DELEUZE, JEAN-MICHEL ITIER, CÉCILE ORSINI, GWÉNAËLLE RET-LECUELLE, SANDRA VIALE
Abstract: The invention provides diamide compounds having muscarinic receptor antagonist and ?2 adrenergic receptor agonist activity, pharmaceutical compositions thereof, and methods of treatment using the same.
Type:
Application
Filed:
June 13, 2016
Publication date:
December 15, 2016
Inventors:
Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric L. STANGELAND, Richard D. WILSON, Rose YEN
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
Abstract: The invention provides sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides sublingual formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Inventors:
Kiran P. Amancha, Chandeshwari S. Chilampalli, Venkat R. Goskonda
Abstract: The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.
Type:
Application
Filed:
August 26, 2016
Publication date:
December 15, 2016
Applicant:
GRUENENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
Abstract: Disclosed herein are methods of treating cancer in a human, where the methods include determining at least one of the following in one or more samples from the human: the presence or absence of an alanine to valine mutation at residue 687 (A687V) in EZH2 in a sample from the human; or the presence or absence of an increased level of H3K27me2 in a sample from the human as compared to a control; and administering to the human an effective amount of the EZH2 inhibitor GSK126 or a pharmaceutically acceptable salt thereof if the A687V mutation is present, or an increased level of H3K27me2 is not present, or both, in the one or more samples, which is indicative of an increased likelihood of increased response rate and/or prolonged progression free survival.
Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
Type:
Application
Filed:
February 9, 2015
Publication date:
December 15, 2016
Inventors:
Robert George BOYLE, David Winter WALKER, Richard Justin BOYCE, Scott PETERSON, Francine FAROUZ, Cong Hung VO
Abstract: Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating a broader range of HCV genotypes and subtypes without being used in combination with interferon and/or ribavirin. Recently, the crystal structure of the core of the HCV E2 protein (E2c) has been determined, providing structural information that can now be used to target the E2 protein and develop drugs that disrupt the early stages of HCV infection by blocking E2's interaction with different host factors. By targeting sites containing conserved E2 amino acids in the CD81 binding site on HCV E2, one might also be able to develop drugs that block HCV infection in a genotype-independent manner.
Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
Type:
Application
Filed:
February 12, 2016
Publication date:
December 15, 2016
Inventors:
Celia Dominguez, Leticia M. Toledo-Sherman, Stephen Martin Courtney, Michael Prime, William Mitchell, Christopher John Brown, Paula C. De Aguiar Pena, Peter Johnson
Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
Type:
Application
Filed:
August 26, 2016
Publication date:
December 15, 2016
Applicant:
XSPRAY MICROPARTICLES AB
Inventors:
Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
Abstract: The present invention relates to a pharmaceutical combination comprising, separately or together, (1) a first agent which is an ALK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof. The invention further relates the use of such combination in the treatment or prevention of proliferative diseases.
Type:
Application
Filed:
August 28, 2014
Publication date:
December 15, 2016
Applicant:
Novartis AG
Inventors:
Jennifer Leslie HARRIS, Nanxin LI, Timothy R SMITH, Yael MOSSE, Andrew WOOD
Abstract: Prodrugs of ibrutinib, pharmaceutical compositions comprising the prodrugs, and methods of using the prodrugs and pharmaceutical compositions for treating autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions are disclosed.
Type:
Application
Filed:
June 11, 2016
Publication date:
December 15, 2016
Inventors:
Mark Quang Nguyen, Archana Gangakhedkar
Abstract: The invention provides novel heterocyclic amines according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Inventors:
Ruoxi LAN, Xiaoling CHEN, Yufang XIAO, Bayard R. HUCK, Andreas GOUTOPOULOS
Abstract: The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.
Type:
Application
Filed:
June 24, 2016
Publication date:
December 15, 2016
Inventors:
Jean-Louis Henri Dasseux, Ronald Barbaras
Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Type:
Application
Filed:
August 25, 2016
Publication date:
December 15, 2016
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
Abstract: Described herein are oral pharmaceutical compositions suitable for chewing, sucking, or buccal dissolution comprising non-systemic corticosteroid soft lozenges, methods for making the same, and methods for treating subjects in need thereof with such lozenges. In particular, the oral composition provides topical, non-systemic administration of one or more active pharmaceutical ingredients to the oral cavity and upper gastrointestinal track, including the esophagus. In one embodiment, the oral pharmaceutical compositions comprise chewable, suckable, or buccally-dissolvable soft lozenges for the treatment of esophageal lesions. The soft lozenges provide topical, non-systemic delivery of corticosteroids to the esophagus and oral cavity.
Type:
Application
Filed:
June 14, 2016
Publication date:
December 15, 2016
Inventors:
Yinyan Zhao, Justin Hughey, Jason Vaughn, Qi Fang
Abstract: The present invention relates to a stable transdermal gel composition comprising Testosterone, a penetration enhancer, a gelling agent with pharmaceutically acceptable excipients. Further, the invention relates to the method of administering the said transdermal gel and its uses thereof.
Abstract: Provided oral testosterone undecanoate compositions can be administered to hypogonadal males with a meal without the fat content of the meal substantially effecting bioavailability.
Type:
Application
Filed:
June 15, 2016
Publication date:
December 15, 2016
Applicant:
Lipocine Inc.
Inventors:
Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari
Abstract: An implant comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the implant is a sustained release, subcutaneous implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Abstract: A pharmaceutical for and a method of treating one of vitamin D deficiency, diabetes and pre-diabetes in an animal comprising the steps A method of treating one of vitamin D deficiency, diabetes and pre-diabetes in an animal comprising the steps of administering a first therapeutic agent and a second therapeutic agent to the animal; providing the first therapeutic agent is one of vitamin D, a pharmaceutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug thereof, and a pharmaceutically acceptable derivative thereof; and providing the second therapeutic agent is one of L-cysteine, glutathione; glycine, glutamate, and glutathione, or a pharmaceutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug thereof, pharmaceutically acceptable derivative thereof, or some combination of thereof.
Type:
Application
Filed:
June 10, 2016
Publication date:
December 15, 2016
Applicant:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Abstract: Described herein are processes for improving the aqueous availability of poorly soluble bioactive materials and bioactive compounds and compositions formed by those processes.
Type:
Application
Filed:
June 10, 2016
Publication date:
December 15, 2016
Applicant:
The Curators of the University of Missouri
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
Type:
Application
Filed:
August 29, 2016
Publication date:
December 15, 2016
Inventors:
Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Applicant:
Achillion Pharmaceuticals, Inc.
Inventors:
Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
Type:
Application
Filed:
August 24, 2016
Publication date:
December 15, 2016
Inventors:
Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
Abstract: The present invention relates to a processed food composition containing, as an active ingredient, psicose, which is a saccharide having the function of stimulating a daidzein conversion into equol by an intestinal microorganism in the human body.
Type:
Application
Filed:
July 13, 2016
Publication date:
December 15, 2016
Inventors:
Taek Beom Kim, Seong Bo Kim, Min Hae Kim, Sung Jae Yang, Jae Hong Han
Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
Type:
Application
Filed:
June 14, 2016
Publication date:
December 15, 2016
Inventors:
John L. Magnani, John T. Patton, Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
Abstract: The present invention provides a composition for wound healing, which includes an effective amount of a citrus polyphenol. Moreover, the present invention also provides a method for improving wound healing and improving fibroblasts migration and/or proliferation, which includes applying an effective amount of citrus polyphenol to the wound and fibroblasts.
Abstract: Provided is an application of baicalin in preparation of a drug for treating ricin poisoning. A Hela cytoprotection test and a mouse ricin poisoning model have verified the recovery effect of baicalin on ricin poisoning.
Type:
Application
Filed:
April 29, 2014
Publication date:
December 15, 2016
Applicants:
JILIN UNIVERSITY, INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
Type:
Application
Filed:
August 23, 2016
Publication date:
December 15, 2016
Applicant:
APRECIA PHARMACEUTICALS COMPANY
Inventors:
Jules JACOB, Lauren BEACH, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT
Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
Type:
Application
Filed:
June 10, 2016
Publication date:
December 15, 2016
Inventors:
Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler
Abstract: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.
Type:
Application
Filed:
August 23, 2016
Publication date:
December 15, 2016
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Valentyn Antochshuk, Mohammed Shameem, Amardeep Singh Bhupender BHALLA
Abstract: The present application relates to compositions comprising selenium compounds, such as 5?-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of formula (I), formula (II), a compound of formula (III) and combinations thereof, and methods of using the same in enhancing mitochondrial function, or treating mitochondrial dysfunction.
Abstract: Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning.
Type:
Application
Filed:
August 23, 2016
Publication date:
December 15, 2016
Inventors:
Nancy HARRISON, I. David MACDONALD, Aniko TAKACS-COX, Robert MILLER